Anavex Life Sciences Corp (AVXL)

[hnbadger1]

"The scientific community has essentially finished with
amyloid - we've identified it, developed drugs, and can
clear it," Dr. Carmichael says. "The fact that clearing
amyloid doesn't substantially change the progression of
the disease means that other things are also going on in
the brains of Alzheimer's disease patients."
At UCLA, researchers are investigating, for example,
how inflammation may impact Alzheimer's disease
progression, as well as the role of the protein tau.
"There are a lot of interesting questions," Dr. Carmichael
says, "that now are even more important to answer."

"What's been surprising, and a bit disappointing, is that
these drugs didn't have as dramatic an effect on
cognitive recovery or cognitive decline,
Dr. Carmichael
says. "They had a very, very
- that's two 'verys'
modest effect on cognition."


https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers#:~:text=Glioblastoma%20and%20Alzheimer's%20disease%20treatments%20advance%20through%20clinical%20trials.&text=A%20personalized%20vaccine%20developed%20by,aggressive%20form%20of%20brain%20cancer.